ClearPoint Neuro, Inc. CLPT R2KR3KPHARMA
Company Overview
ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States. The company offers ClearPoint systems, such as ClearPoint hardware, which includes head fixation frame, computer workstation, and in-room monitor; and ClearPoint disposables, which consist of SmartFrame trajectory device, a hand controller and related accessories, and its SmartFlow Neuro cannula. It also provides ClearPoint software, which guides the physician in surgical planning, device alignment, navigation to the target, and procedure monitoring; ClearPoint Prism Neuro laser therapy system to necrotize or coagulate soft tissue; and IRRAflow system, an active fluid exchange platform. In addition, the company offers consulting services to its pharmaceutical and other medical technology partners, such as benchtop testing, preclinical studies, clinical trial support, regulatory consultation, and translation from the preclinical to the clinical setting. It has licenses and collaboration agreements with Koninklijke Philips N.V., UCB Biopharma SRL, Clinical Laserthermia Systems AB, University of California, San Francisco, and NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
Why Investors Should Care
Revenue has grown at a 19.1% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $36.97M (+17.8% YoY); net profit $-25.54M.
- Trailing 12 Months Year-on-year growth — revenue +18.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 19.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 19.15% |
| 1 Year: | 18.10% |
Stock Price Performance
| 1 Year: | +17.11% |
| 6 Months: | +39.60% |
| 3 Months: | +8.30% |
| 1 Month: | +4.26% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)40.66 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 19.1% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 52.8% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CLPT ClearPoint Neuro, Inc. R2KR3KPHARMA | 13.96 | -11.83 | $425.84M | 0.00% | -27.78% | - | 19.15% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2013 | Sep 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.57M | 5.03M | 5.20M | 5.15M | 5.43M | 5.95M | 5.76M | 7.64M | 7.86M | 8.12M | 8.48M | 9.21M | 8.86M | 12.13M | 10.88M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.68M | 2.62M | 2.61M | 2.27M | 3.04M | 3.23M | 3.25M | 3.68M | 3.20M | 3.13M | 3.27M | 4.53M | 4.99M | 4.85M | 5.13M | 5.56M | 5.60M | 7.76M | 6.71M |
| Operating Income | -2.18M | -1.86M | 2.19M | -2.22M | -2.62M | -2.94M | -2.68M | -1.93M | -1.93M | -2.06M | -1.71M | -1.35M | -1.82M | -1.33M | -1.43M | -1.64M | -1.21M | -972.25K | -1.29M | -910.53K | -1.21M | -1.48M | -1.27M | -2.18M | -3.41M | -3.80M | -3.86M | -4.20M | -3.79M | -5.71M | -7.13M | -4.90M | -4.22M | -4.72M | -5.16M | -6.16M | -5.68M | -5.28M | -8.48M | -10.24M |
| Net Income | -1.35M | -3.19M | 2.63M | -1.59M | -3.65M | -3.95M | -3.06M | -245.40K | -2.04M | -1.78M | -2.56M | -1.66M | -2.00M | -1.43M | -1.64M | -1.88M | -1.43M | -1.22M | -1.55M | -1.12M | -2.06M | -1.66M | -1.48M | -2.54M | -3.74M | -3.98M | -3.96M | -4.30M | -3.79M | -5.61M | -7.05M | -4.81M | -4.15M | -4.41M | -4.97M | -6.03M | -5.84M | -5.89M | -9.55M | -11.34M |
| Diluted EPS | -0.02 | - | 0.04 | -0.03 | - | -0.05 | -0.04 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.13 | -0.17 | -0.18 | -0.17 | -0.18 | -0.15 | -0.23 | -0.29 | -0.20 | -0.16 | -0.16 | -0.18 | -0.22 | -0.21 | -0.21 | -0.32 | -0.38 |
| R&D Expense | 741.82K | 725.30K | 817.62K | 898.42K | 873.37K | 527.51K | 426.93K | 480.28K | 657.19K | 749.94K | 691.33K | 557.70K | 1.08M | 589.72K | 546.33K | 665.31K | 617.24K | 584.54K | 697.80K | 761.88K | 818.00K | 812.00K | 1.14M | 1.56M | 2.11M | 2.60M | 2.90M | 2.41M | 2.65M | 3.02M | 3.60M | 2.43M | 2.62M | 3.12M | 3.31M | 3.38M | 3.83M | 3.45M | 4.52M | 4.63M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.67M | 3.82M | 5.06M | 3.93M | 3.60M | 4.59M | 5.75M | 7.38M | 7.35M | 11.22M | 12.83M | 16.30M | 20.55M | 23.95M | 31.39M | 36.97M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | 9.12M | 11.12M | 13.53M | 13.61M | 19.12M | 22.69M |
| Operating Income | -9.52M | -5.92M | -3.13M | -7.47M | -5.32M | -8.97M | -7.49M | -6.34M | -5.25M | -4.59M | -6.22M | -13.37M | -16.33M | -22.45M | -19.73M | -24.16M |
| Net Income | -9.45M | -8.31M | -5.88M | -7.09M | -4.52M | -8.45M | -8.07M | -7.17M | -6.16M | -5.54M | -6.78M | -14.41M | -16.43M | -22.09M | -18.91M | -25.54M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | -0.69 | -0.68 | -0.90 | -0.70 | -0.90 |
| R&D Expense | 5.68M | 4.25M | 2.48M | 2.92M | 3.30M | 1.96M | 2.63M | 2.81M | 2.31M | 2.81M | 4.69M | 9.28M | 10.89M | 11.71M | 12.39M | 13.90M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 3.03M | 5.55M | 7.87M | 13.39M | 9.94M | 7.40M | 13.90M | 7.86M | 11.93M | 29.52M | 65.58M | 55.49M | 42.66M | 39.19M | 97.75M |
| Total Equity | -9.89M | -15.34M | -21.84M | -7.87M | -6.83M | -100.33K | -1.98M | -756.07K | 5.83M | 1.51M | 4.59M | 2.38M | 48.79M | 36.89M | 21.17M | 25.39M | 28.02M |
| Cash & Equivalents | 2.57M | 1.58M | 145.48K | 1.62M | 3.52M | 9.24M | 5.41M | 3.32M | 9.29M | 3.10M | 5.70M | 20.10M | 54.11M | 27.61M | 23.14M | 20.10M | 45.92M |
| Long Term Debt | - | - | - | - | - | 11.01M | 8.11M | 4.49M | 4.92M | 3.48M | 2.07M | 21.28M | 9.84M | 9.89M | 9.95M | - | 49.08M |
| Total Liabilities | - | - | 24.87M | 13.42M | 14.71M | 13.49M | 11.92M | 8.16M | 8.07M | 6.35M | 7.34M | 27.14M | 16.79M | 18.60M | 21.49M | 13.80M | 69.73M |
| Current Liabilities | - | - | 14.59M | 6.31M | 10.09M | 4.92M | 7.65M | 3.02M | 4.40M | 1.87M | 3.83M | 3.20M | 4.75M | 6.79M | 7.43M | 10.35M | 10.77M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -7.71M | -6.24M | -7.43M | -7.78M | -7.25M | - | -5.82M | -5.99M | -4.63M | -2.85M | -7.81M | -12.70M | -16.17M | -13.72M | -8.95M | -23.93M |
| Investing Cash Flow | -61.70K | -26.10K | -127.45K | -174.47K | -48.13K | - | -101.00K | -26.75K | -63.49K | -160.00K | -482.00K | -168.00K | -10.74M | 8.95M | -275.00K | 615.00K |
| Financing Cash Flow | 6.78M | 4.83M | 9.04M | 9.85M | 13.03M | - | 3.83M | 11.99M | -1.49M | 5.61M | 22.69M | 46.88M | 409.00K | 296.00K | 6.19M | 50.18M |
| Capital Expenditure | -61.70K | -26.10K | -127.45K | -74.47K | -48.13K | -76.88K | -101.00K | -26.75K | -63.49K | -10.00K | -41.00K | -168.00K | -253.00K | -717.00K | -275.00K | -522.00K |
| Free Cash Flow | -7.77M | -6.27M | -7.56M | -7.85M | -7.30M | - | -5.92M | -6.02M | -4.69M | -2.86M | -7.85M | -12.87M | -16.42M | -14.44M | -9.22M | -24.45M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | 71.1% | 68.2% | 65.8% | 56.8% | 60.9% | 61.4% |
| Operating Margin % | -356.5% | -155.1% | -61.9% | -190.2% | -147.6% | -195.3% | -130.3% | -85.9% | -71.4% | -41.0% | -48.5% | -82.1% | -79.5% | -93.7% | -62.9% | -65.4% |
| Net Margin % | -354.2% | -217.7% | -116.2% | -180.3% | -125.5% | -183.9% | -140.4% | -97.1% | -83.8% | -49.4% | -52.9% | -88.4% | -80.0% | -92.2% | -60.3% | -69.1% |
| ROE % | 61.6% | 38.1% | 74.7% | 103.7% | 4,509.8% | 426.5% | 1,067.3% | -123.0% | -408.2% | -120.8% | -285.3% | -29.5% | -44.6% | -104.3% | -74.5% | -91.1% |
| ROCE % | - | 51.2% | 413.6% | 337.1% | -62.8% | -393.0% | -170.9% | -66.7% | -87.6% | -56.8% | -23.6% | -22.0% | -33.5% | -63.7% | -68.4% | -27.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 7.80% | 2.38M | $37.01M |
| 2 | MAK Capital One LLC | 7.79% | 2.38M | $36.94M |
| 3 | Vanguard Capital Management LLC | 4.04% | 1.23M | $19.17M |
| 4 | State Street Corporation | 2.68% | 816.55K | $12.70M |
| 5 | Geode Capital Management, LLC | 2.46% | 749.93K | $11.66M |
| 6 | Lane Generational LLC | 1.46% | 444.83K | $6.92M |
| 7 | UBS Group AG | 1.41% | 428.63K | $6.67M |
| 8 | Millennium Management Llc | 1.17% | 357.68K | $5.56M |
| 9 | Brown Advisory Inc. | 1.07% | 325.91K | $5.07M |
| 10 | Compass Financial Management LLC | 0.97% | 295.68K | $4.60M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CLPT
ClearPoint Neuro (CLPT) Stock Sees Fair Value Cut As Analysts Factor In Heavier Investment - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxQQkR3X3B6WHBQeEp2RXlqMnM5cXNxVlZOSGpIbWJBRnRCa1dhQjZtUnk3bC1GR3JuNWh3TGVneTAyVVg4UmpUbkxDX3hicGlzWDFnTTFNdXpYa0VBNmQ2Y0JQWnFxbUZjRkJDNnp5NGlpYmpZMjlNMzl0cmhjTEJrS2FtRGl2YVdwZ3JIOV…
How (CLPT) Movements Inform Risk Allocation Models - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxPVVlHRjRhOW04QVNCZ2d1N01GdkdqQmVvN0cwRU54QmxHZXByZUdES2VTVTV4aWpDaEJib1hKVGlkYUEyWnFFS01YQ3FQazlmdHJqRE93ZTJxR1ZuV1BBeE92NUthMjFIZ3dnaXN6ZlFXLTlHSi0xVVJJMnpxR0wzSGFrNUZRNGxEdUJnVX…
ClearPoint Neuro Inc. (CLPT) Stock Falls on Q4 2025 Earnings - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxPWTlqRWx4MW5QZ0ltQ0xqRlNMSTQ2ODcxVGJYTURja2lIOHV0TEJIWWJXQkF0d2dEOWtFTHA4NmZUZHEzc0sweFg4OHFZZTJtX2xva1lndWFFRjJtcW9mdTJoZnF3cTAzSUZFQ1JVN2hPWFpucXVjaVFrRGlFdjNEQkdlQWExY3hLWEFFYW…
CLPT Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE1IY29ubkJWWUFFRXltRWo5cTRQSkhQVlgzaWVDRjkzaDdTbXNxQWhhYmJBQ2dsZ3F4Y0lUVjVPcG01R180WUhRa3pSd016T2lUZkVhT2U1M0xRWGlnaU9JTzkxRjdaN19BaFpVNHloMWFveXZiZkkwNTh3?oc=5" target="_blank">CLP…
ClearPoint Neuro Company Profile & Introduction - Moomoo
<a href="https://news.google.com/rss/articles/CBMi9wJBVV95cUxPUE5uWmhBMDRkSXJ2ZW9yQmtRX1ZDSUlvMUc1QVNZVzJzQVI5ZURuNndGZVRRMVdJMEt4aDZsSW9FeDhMeF9xZnVDTEdKUzZqYmVHUFBmWEk0MjlXdy1uY2hrRmh4cHA2SjdndVo3WUY2c1BxNlhFaERyMGFtWmE2OW5lRnZmME9tMFZ1dj…
Why I've (Reluctantly) Sold My ClearPoint Neuro Position (NASDAQ:CLPT) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxNb0k0Z1I3TlRxelFUY1pLOGk2dnJlLS1uNkk2SWdaQ3RKT3BBeHBkV2xpMTJFb1pMS2lobDRNbVNDSVdzeDh5NE1JbmNTdzdYb18zUGdSa3J1ZlBIMjBpdVBVSVFNbjFTdWV4NkJfbXo4cGxjSlBtOFptUXRfd3VmVDRyZW9EVUxCNG1BOE…
CLPT — Frequently Asked Questions
What is the current share price of ClearPoint Neuro, Inc. (CLPT)?
As of 2026-09-07 16:24 PDT, ClearPoint Neuro, Inc. (CLPT) trades at $13.96 on NasdaqCM. Its 52-week range is $8.66 to $29.60.
What is the market capitalisation of CLPT?
ClearPoint Neuro, Inc. (CLPT) has a market capitalisation of $425.84M on NasdaqCM.
What is the P/E ratio of CLPT?
CLPT trades at a trailing price-to-earnings (P/E) ratio of -11.83. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 40.25.
Is CLPT a good stock to buy?
This page provides a data-driven analysis of ClearPoint Neuro, Inc. (CLPT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.